Contribution: Industrial Research Assistance Program – Contributions to Firms
Archis Lifesciences Inc.
$74,800.00
Development of Pharmaceutical products for Canada.
FY 2022-23 · 2022-11-01
Summary
Archis Life Sciences (ALS) plans to develop or acquire products that fulfill unmet medical needs, manage the required development and regulatory approval process, and market those products in Canada.
Department
Program
Industrial Research Assistance Program – Contributions to FirmsIndustrial Research Assistance Program-Contributions to Firms (linked with high confidence)
Recipient
Location
Winnipeg|Winnipeg, Manitoba, Canada
Recipient Type
For-profit organization
Business Number
731778080
Type
Contribution
Source
Proactive Disclosure - Grants and Contributions
Amendments
Each version of the agreement as published, oldest first, with its total as of that version. The amount above is the latest.
| Amendment | Date | Fiscal Year | Total |
|---|---|---|---|
| 0 | 2022-11-01 | 2022-23 | $74,800.00 |
| 1 | 2022-11-01 | 2022-23 | $74,800.00 |
As published
Additional Information
This agreement has been amended 1 time(s). The end date of this agreements has been modified by 61 days.
Additional Information (French)
Cet accord a été modifié 1 fois La date de fin du présent accord a été changé de 61 jours.
Agreement End Date
2023-07-31
Agreement Number
997367
Agreement Start Date
2022-11-01
Agreement Title
Development of Pharmaceutical products for Canada.
Agreement Title (French)
Développement de produits pharmaceutiques pour le Canada
Agreement Type
Contribution
Agreement Value
$74,800.00
Amendment Date
2023-03-21
Amendment Number
1
Coverage
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation. | Les projets des Contributions aux entreprises stimulent la création de richesse au Canada grâce à l’innovation technologique.
Description
Archis Life Sciences (ALS) plans to develop or acquire products that fulfill unmet medical needs, manage the required development and regulatory approval process, and market those products in Canada.
Description (French)
Archis Life Sciences (ALS) prévoit de développer ou d’acquérir des produits qui répondent à des besoins médicaux non satisfaits, de gérer le développement nécessaire et le processus d’approbation réglementaire ainsi que de commercialiser ces produits au Canada.
Expected Results
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Expected Results (French)
Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation
Federal Riding
Winnipeg South Centre
Federal Riding (French)
Winnipeg-Centre-Sud
Federal Riding Number
46014
NAICS Code
3254
Organization Code
nrc-cnrc
Organization
National Research Council Canada | Conseil national de recherches Canada
Program Name
Industrial Research Assistance Program – Contributions to Firms
Program Name (French)
Programme d’aide à la recherche industrielle – Contributions aux entreprises
Program Purpose
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Program Purpose (French)
Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation
Recipient Business Number
731778080
Recipient City
Winnipeg|Winnipeg
Recipient Country
CA
Recipient Legal Name
Archis Lifesciences Inc.
Recipient Postal Code
R3P 2R3
Recipient Province or Territory
MB
Recipient Type
F
Reference Number
172-2022-2023-Q3-997367
